Trial Profile
A phase III, multicenter, open-label study to evaluate the control of gastric acid secretion with esomeprazole in patients with gastric acid hypersecretory states including idiopathic hypersecretion and Zollinger-Ellison syndrome for 12 months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2010
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary)
- Indications Hyperchlorhydria; Zollinger-Ellison syndrome
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 Apr 2009 Actual end date (July 2005) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Actual initiation date (July 2003) added as reported by ClinicalTrials.gov.
- 16 Oct 2006 Status change